6533b857fe1ef96bd12b4ec3

RESEARCH PRODUCT

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

Maria Enza MitraCaterina Giovanna ValentiniGiuliana FarinaAnnamaria NosariLivio PaganoMassimo OffidaniMorena CairaBrunella PosteraroMaurizio SanguinettiPierluigi VialeMonica MorselliLuana FianchiAnna CandoniRosa FanciGiuseppe LeoneMaria Elena Tosti

subject

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia

description

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

yearjournalcountryeditionlanguage
2010-03-01
10.1111/j.1469-0691.2009.02832.xhttps://hdl.handle.net/11380/1294113